Medtronic is the predominant player in the energy-based therapies market. With global sales of nearly $4.9 billion attributable to energy-based products, it controls over half of the cardiac rhythm market and almost a quarter of all energy-based product sales. Boston Scientific, also focusing on cardiac arrhythmias, comes next in the revenues table with a $2. 9 billion share. St. Jude Medical, the joint number three player enjoys sales of nearly $2 billion for energy therapies such as implantable defribrillators and pacemakers using electrical energy to restore normal heart rhythm . Varian Medical shares the number three spot with almost $2 million in sales. Varian is the world’s leading manufacturer of integrated cancer therapy systems and markets a full line of linear accelerators for radiation therapy.
With sales of over $800 million for energy-based products, Biosense Webster, a Johnson & Johnson company, comes next in market share. Then comes Covidien (formerly Tyco Healthcare) with its member company Valleylab specialising in devices for electrosurgery and vessel sealing. Smith & Nephew generates sales of $600 million from energy-based therapies including devices for radiofrequency and hydro-ablation. The remaining three companies in the "top ten" each generate annual revenues in the $200-300 million range from energy-based devices; they are Arthrocare, Getinge and Olympus.
Market Leaders in Energy-Based Therapies
Biosense Webster (J&J)
RF, Microwave, Ultrasound
Soft tissue ablation
Gynaecology, ENT, soft tissue ablation
Smith & Nephew
Soft tissue ablation, Capsular shrinkage
Saphenous vein closure
Source: MedMarket Diligence, LLC
The above is an excerpt from report #A125, "Ablation Technologies Worldwide Market, 2008," published September 2008.